AC Immune (ACIU) Depreciation & Amortization - Total (2015 - 2016)
AC Immune (ACIU) reported Depreciation & Amortization - Total of -$278006.8 for Q4 2016, up 4.14% year-over-year from -$266947.0 in Q1 2016, and up 4.14% on a QoQ basis from -$290022.7 in Q4 2015.
AC Immune (ACIU) has 2 years of Depreciation & Amortization - Total data on file, last reported at -$278006.8 in Q4 2016.
- Quarterly Depreciation & Amortization - Total rose 4.14% year-over-year to -$278006.8 in Q4 2016, while the trailing twelve-month figure through Sep 2017 was -$278006.8 (up 4.14% YoY) and the FY2025 annual result came in at -$1.7 million, up 1.95% from the prior year.
- Depreciation & Amortization - Total climbed to -$278006.8 in Q4 2016 per ACIU's latest filing, from -$290022.7 in the prior quarter.
- Across five years, Depreciation & Amortization - Total topped out at -$278006.8 in Q4 2016 and bottomed at -$290022.7 in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -278,006.79 |
| Dec 31, 2015 | -290,022.68 |